Actively Recruiting

Phase 3
Age: 12Years +
All Genders
ID06933472

A Randomized, Double-Blind, Multi-Regional Phase 3 Study Evaluating AP301 for Serum Phosphorus Control in Dialysis Patients with Hyperphosphatemia

Led by Alebund Pharmaceuticals · Updated on 2026-01-29

264

Participants Needed

42

Research Sites

29 weeks

Total Duration

On this page

Sponsors

A

Alebund Pharmaceuticals

Lead Sponsor

F

Fortrea

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating AP301, a novel iron-based phosphate binder, in patients with chronic kidney disease who are receiving maintenance dialysis and have elevated blood phosphate levels. This phase 3, randomized, double-blind study aims to determine whether AP301 lowers blood phosphate and how it affects serum calcium, calcium times phosphate, and intact parathyroid hormone levels. The trial also assesses any discomfort or medical problems during treatment and its impact on quality of life in Chinese patients. Participants will first stop all phosphate-lowering medications. They will then take either AP301 or a low-dose comparator (considered ineffective) three times daily for 8 weeks. Following this, all participants receive AP301 three times daily for 24 weeks, with dose adjustments based on blood phosphate levels and physician judgment. Finally, participants will take either AP301 or the comparator three times daily for 3 weeks. Additional treatments may be given if blood phosphate levels become too high or low. During the study, participants will undergo regular assessments including blood tests to monitor serum phosphate, calcium, and parathyroid hormone levels. Electrocardiogram tests will measure changes in QT intervals. Safety is monitored by tracking adverse events throughout the trial, which lasts up to 37 weeks. The primary outcome is the change in serum phosphate concentration from baseline to the end of week 8, with ongoing evaluations over the entire study period.

CONDITIONS

Brief Title

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

Who Can Participate

Age: 12Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed and dated informed consent form
  • Age 12 years or older at signing
  • Receiving dialysis for at least 3 months before and during the study
  • For hemodialysis patients, spKt/V ≥ 1.2; for peritoneal dialysis patients, total Kt/V ≥ 1.7/week
  • Serum phosphate levels within 1.13 to 2.58 mmol/L (3.5 to 8.0 mg/dL) at screening
  • After washout, serum phosphate levels between 1.94 and 3.23 mmol/L (6.0 to 10.0 mg/dL)
Not Eligible

You will not qualify if you...

  • History or plans for kidney transplantation
  • History or plans for parathyroid intervention within 6 months before signing consent
  • Serum calcium below 1.9 mmol/L (7.6 mg/dL) or above 2.75 mmol/L (11 mg/dL) at screening
  • Serum intact parathyroid hormone above 127 pmol/L (1200 pg/mL) at screening
  • Presence of significant gastrointestinal disorders
  • History of gastrectomy, duodenectomy, or gastrointestinal surgery within 3 months before signing consent
  • Known allergy to any AP301 ingredient or severe allergy history requiring emergency care
  • Females who are breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey: What to Expect

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Treatment

Duration - 8 weeks

Participants take the study medication AP301 or a low dose version orally three times a day with meals to control serum phosphate levels.

Regular visits during treatment period

Follow-up

Duration - Up to 29 weeks after treatment

Participants are monitored for safety and changes in serum phosphate and other blood levels after treatment ends.

Visits up to Week 37

Trial Site Locations

Total: 42 locations

1

Renal Consultants Medical Group

Granada Hills, California, United States, 91344

Actively Recruiting

2

North America Research Institute - San Dimas

San Dimas, California, United States, 91773

Actively Recruiting

3

North America Research Institute - San Dimas

San Dimas, California, United States, 91773

Actively Recruiting

4

Rocky Mountain Kidney Care - Lone Tree

Lone Tree, Colorado, United States, 80124

Actively Recruiting

5

PACT Kidney Care - Orange

Orange, Connecticut, United States, 06477

Actively Recruiting

6

US Renal Care - Fort Myers South

Fort Myers, Florida, United States, 33912

Actively Recruiting

7

Nephrology & Hypertension Specialists

Dalton, Georgia, United States, 30720

Actively Recruiting

8

Renal Associates Of Baton Rouge, LLC

Baton Rouge, Louisiana, United States, 70808

Actively Recruiting

9

Nephrology Associates, P.C. - Columbus

Columbus, Mississippi, United States, 38801

Actively Recruiting

10

Nephrology & Hypertension Associates Ltd - Tupelo

Tupelo, Mississippi, United States, 38801

Actively Recruiting

11

High Desert Nephrology Association - US Renal Care

Gallup, New Mexico, United States, 87301

Actively Recruiting

12

US Renal Care - West Cheektowaga

Cheektowaga, New York, United States, 14215

Actively Recruiting

13

NY Kidney & Hypertension Medicine

Ridgewood, New York, United States, 11385

Actively Recruiting

14

US Renal Care - Alexis

Toledo, Ohio, United States, 43613

Actively Recruiting

15

Dallas Renal Group - Dallas

Dallas, Texas, United States, 75237

Actively Recruiting

16

US Renal Care - Bluebonnet

Fort Worth, Texas, United States, 76110

Actively Recruiting

17

Gamma Medical Research

McAllen, Texas, United States, 78503

Actively Recruiting

18

US Renal Care - South San Antonio

San Antonio, Texas, United States, 78211

Actively Recruiting

19

US Renal Care - Hill Country

San Antonio, Texas, United States, 78251

Actively Recruiting

20

Peking University First Hospital

Beijing, Beijing Municipality, China, 100035

Actively Recruiting

21

Beijing Tsinghua Chang Gung Hospital

Beijing, Beijing Municipality, China, 102218

Actively Recruiting

22

Peking University International Hospital

Beijing, Beijing Municipality, China, 102218

Actively Recruiting

23

The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China, 361003

Actively Recruiting

24

Henan Provincial People's Hospital

Zhengzhou, Henan, China, 450003

Actively Recruiting

25

Zhengzhou University-First Affiliated Hospital

Zhengzhou, Henan, China, 450003

Actively Recruiting

26

Huazhong University of Science and Technology-Tongji Medical College - Wuhan Union Hospital

Wuhan, Hubei, China, 430022

Actively Recruiting

27

Wuhan University People's Hospital

Wuhan, Hubei, China, 430060

Actively Recruiting

28

Central South University-The Third Xiangya Hospital

Changsha, Hunan, China, 410013

Actively Recruiting

29

Southeast University-Zhongda Hospital

Nanjing, Jiangsu, China, 210009

Actively Recruiting

30

Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)

Nanjing, Jiangsu, China, 210029

Actively Recruiting

31

Nantong University-Affiliated Hospital

Nantong, Jiangsu, China, 226001

Actively Recruiting

32

Nanjing Medical University-Wuxi People's Hospital (Wuxi No.1 People's Hospital)

Wuxi, Jiangsu, China, 214023

Actively Recruiting

33

Subei People's Hospital

Yangzhou, Jiangsu, China, 225002

Actively Recruiting

34

Jiangxi Provincial People's Hospital

Nanchang, Jiangxi, China, 330006

Actively Recruiting

35

Qingdao University-The Affiliated Hospital

Qingdao, Shandong, China, 266000

Actively Recruiting

36

Yantai Yuhuangding Hospital

Yantai, Shandong, China, 264099

Actively Recruiting

37

Shanghai Jiao Tong University School of Medicine (SJTUSM)-Renji Hospital

Shanghai, Shanghai Municipality, China, 200000

Actively Recruiting

38

Fudan University-Zhongshan Hospital

Shanghai, Shanghai Municipality, China, 200032

Actively Recruiting

39

Fudan University-Huashan Hospital

Shanghai, Shanghai Municipality, China, 200040

Actively Recruiting

40

Children's Hospital of Fudan University

Shanghai, Shanghai Municipality, China, 200080

Not Yet Recruiting

41

Shanghai Tongren Hospital

Shanghai, Shanghai Municipality, China, 200336

Actively Recruiting

42

Sichuan Provincial People's Hospital

Chengdu, Sichuan, China, 610072

Actively Recruiting

Loading map...

Research Team

W

Weifeng Zhang, M.D.

B

Bobby Zang

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Stu...

Hyperphosphatemia

Actively Recruiting

26 locations

A Prospective Study on Predicting Cardiovascular Events and ...

Chronic Kidney Disease Stage 5

Actively Recruiting

1 location

A Qualitative Exploration of Healthcare Professionals' Persp...

Perspective of Healthcare Professionals Haemodialysis Needling

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here